Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
444 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00004049 | SR-45023A in Treating Patients With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 36 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Aug 29, 2018 | clinicaltrials |
| NCT02575781 | A Study of SAR428926 in Patients With Advanced Solid Tumors | completed | Phase 1 | 34 | SanofiINDUSTRY | 3 | Aug 22, 2018 | clinicaltrials |
| NCT01636479 |
| Phase 1 Safety Testing of SAR405838 |
| completed |
| Phase 1 |
| 77 |
| SanofiINDUSTRY |
| 3 |
| May 17, 2018 |
| clinicaltrials |
| NCT00098345 | Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer | completed | Phase 2 | 40 | Genzyme, a Sanofi CompanyINDUSTRY | 2 | May 7, 2018 | clinicaltrials |
| NCT01571284 | Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen | completed | Phase 3 | 781 | SanofiINDUSTRY | 23 | Apr 17, 2018 | clinicaltrials |
| NCT00995293 | Taxotere (Docetaxel) New Indication: Squamous Cell Carcinoma of the Head and Neck (SCCHN) Treatment Registration Trial | completed | Phase 3 | 240 | SanofiINDUSTRY | 1 | Mar 2, 2018 | clinicaltrials |
| NCT02664103 | Study of Capecitabine and Cyclophosphamide Administered as a Single Pill in Patients With Advanced Breast Cancer(METRO-ABC) | completed | Phase 2 | 2 | SanofiINDUSTRY | 1 | Feb 1, 2018 | clinicaltrials |
| NCT00364351 | Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy | completed | Phase 3 | 1,574 | Genzyme, a Sanofi CompanyINDUSTRY | 22 | Jan 25, 2018 | clinicaltrials |
| NCT00500292 | A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer | completed | Phase 2 | 109 | Genzyme, a Sanofi CompanyINDUSTRY | 6 | Jan 25, 2018 | clinicaltrials |
| NCT01472887 | SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients(STARLYTE) | completed | Phase 2 | 61 | SanofiINDUSTRY | 9 | Jan 25, 2018 | clinicaltrials |
| NCT01718353 | Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(TAXYNERGY) | completed | Phase 2 | 63 | SanofiINDUSTRY | 2 | Nov 20, 2017 | clinicaltrials |
| NCT01593228 | Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial | completed | Phase 3 | 37 | SanofiINDUSTRY | 4 | Sep 19, 2017 | clinicaltrials |
| NCT01288573 | A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone | completed | Phase 1 / Phase 2 | 46 | Genzyme, a Sanofi CompanyINDUSTRY | 12 | May 16, 2017 | clinicaltrials |
| NCT01156870 | First in Man Study of SAR566658 Administered in Patients With CA6-Positive and Refractory Solid Tumor | completed | Phase 1 | 114 | SanofiINDUSTRY | 3 | May 10, 2017 | clinicaltrials |
| NCT01539655 | Study in Healthy Volunteers to Assess Effect of Omeprazole and Ranitidine on the Pharmacokinetics of Vandetanib(Vandetanib) | completed | Phase 1 | 34 | SanofiINDUSTRY | 1 | May 2, 2017 | clinicaltrials |
| NCT02109250 | CAPRELSA® REGISTRY: a Belgian Registry to Evaluate the Use of Vandetanib (Caprelsa®) in Current Clinical Practice(CaprelsaReg) | completed | — | 10 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | May 2, 2017 | clinicaltrials |
| NCT02520102 | Open Label Study of Sargramostim Among Patients Receiving Myelosuppressive Induction Chemotherapy for Acute Myelogenous Leukemia | withdrawn | Phase 2 | 0 | SanofiINDUSTRY | 0 | Apr 20, 2017 | clinicaltrials |
| NCT01308580 | Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer(PROSELICA) | completed | Phase 3 | 1,200 | SanofiINDUSTRY | 22 | Apr 17, 2017 | clinicaltrials |
| NCT01204125 | Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients(SOLTI NEOPARP) | completed | Phase 2 | 141 | SanofiINDUSTRY | 3 | Mar 22, 2017 | clinicaltrials |
| NCT01882868 | A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan | completed | Phase 2 | 62 | SanofiINDUSTRY | 1 | Mar 14, 2017 | clinicaltrials |
| NCT00358956 | A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer | completed | Phase 2 | 19 | Genzyme, a Sanofi CompanyINDUSTRY | 8 | Jan 30, 2017 | clinicaltrials |
| NCT02441894 | Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer(PEGAZUS) | completed | Phase 4 | 21 | SanofiINDUSTRY | 1 | Jan 24, 2017 | clinicaltrials |
| NCT00686036 | Trial Assessing Zactima Against Placebo in Prostate Cancer Subjects Undergoing Intermittent Androgen Deprivation Hormonal Therapy(ZENITH) | terminated | Phase 2 | 17 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Dec 21, 2016 | clinicaltrials |
| NCT00659438 | Efficacy and Safety of Zactima™ in Patients With Castration-refractory Metastatic Prostate Cancer | completed | Phase 2 | 95 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Dec 5, 2016 | clinicaltrials |
| NCT00752986 | ZACtima FASlodex Trial in Postmenopausal Advance Breast Cancer Patients Instead of ZACtima FASlodex Trial(ZACFAST) | terminated | Phase 2 | 39 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Dec 5, 2016 | clinicaltrials |
| NCT01661179 | Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma | completed | Phase 1 / Phase 2 | 14 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Dec 5, 2016 | clinicaltrials |
| NCT01670721 | Colorectal Cancer Metastatic(AFEQT) | completed | Phase 3 | 175 | SanofiINDUSTRY | 1 | Nov 28, 2016 | clinicaltrials |
| NCT00021255 | Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer | completed | Phase 3 | 3,222 | SanofiINDUSTRY | 42 | Nov 15, 2016 | clinicaltrials |
| NCT01661270 | A Study of Aflibercept Versus Placebo With FOLFIRI in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin Chemotherapy(AFLAME) | completed | Phase 3 | 332 | SanofiINDUSTRY | 5 | Oct 18, 2016 | clinicaltrials |
| NCT00753714 | Zactima in Non Small Cell Lung Cancer (NSCLC) ELderly Patients In Combination With or Versus Gemcitabine(ZELIG) | completed | Phase 2 | 124 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Oct 17, 2016 | clinicaltrials |
| NCT00508001 | Phase II Study of Best Support Care (BSC) Plus ZD6474(Vandetanib) in Patients With Inoperable Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 67 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Oct 10, 2016 | clinicaltrials |
| NCT00597116 | An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma | terminated | Phase 2 | 25 | Genzyme, a Sanofi CompanyINDUSTRY | 2 | Oct 10, 2016 | clinicaltrials |
| NCT00753675 | Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer(VANGOGH) | completed | Phase 2 | 174 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Oct 10, 2016 | clinicaltrials |
| NCT00777179 | Phase II of Zactima Maintenance for Locally Advanced or Metastatic Non-small-cell Lung Carcinoma (NSCLC) Following Platinum-doublet Chemotherapy | completed | Phase 2 | 117 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Oct 10, 2016 | clinicaltrials |
| NCT00862836 | Addition of Vandetanib to Standard Therapy Pegliposomal Doxorubicin (PLD)(ZACFAST) | terminated | Phase 1 / Phase 2 | 15 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Oct 10, 2016 | clinicaltrials |
| NCT00454116 | A Phase II, Double Blind Study of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients | completed | Phase 2 | 106 | Genzyme, a Sanofi CompanyINDUSTRY | 6 | Oct 7, 2016 | clinicaltrials |
| NCT00498797 | E3-Hormone Refractory Prostrate Cancer Taxotere Combination | completed | Phase 2 | 86 | SanofiINDUSTRY | 5 | Oct 7, 2016 | clinicaltrials |
| NCT00312377 | ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer(ZODIAC) | completed | Phase 3 | 1,690 | Genzyme, a Sanofi CompanyINDUSTRY | 25 | Sep 30, 2016 | clinicaltrials |
| NCT00404924 | ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures | completed | Phase 3 | 1,140 | Genzyme, a Sanofi CompanyINDUSTRY | 22 | Sep 30, 2016 | clinicaltrials |
| NCT00494481 | E3 Breast Cancer Taxotere Combination | completed | Phase 2 | 64 | Genzyme, a Sanofi CompanyINDUSTRY | 5 | Sep 30, 2016 | clinicaltrials |
| NCT00503711 | Phase I Chinese PK | completed | Phase 1 | 36 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Aug 31, 2016 | clinicaltrials |
| NCT01757470 | Vandetanib Risk Minimisation Effectiveness | completed | — | 12 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Aug 31, 2016 | clinicaltrials |
| NCT00206726 | Alemtuzumab/Fludarabine for Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (B-CLL)(ECO-1) | completed | Phase 2 | 60 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Aug 29, 2016 | clinicaltrials |
| NCT00450138 | Open Label, Phase I ZD6474 Head and Neck Cancer Study | completed | Phase 1 | 48 | SanofiINDUSTRY | 1 | Aug 29, 2016 | clinicaltrials |
| NCT00681798 | Dose Escalation Study With Zactima and Chemotherapy in Metastatic Pancreas Carcinoma | completed | Phase 1 | 8 | SanofiINDUSTRY | 1 | Aug 29, 2016 | clinicaltrials |
| NCT00496275 | Phase I Combination With Vinorelbine or Gemcitabine Plus Cisplatin in Locally Advanced or Metastatic NSCLC | completed | Phase 1 | 17 | Genzyme, a Sanofi CompanyINDUSTRY | 0 | Aug 26, 2016 | clinicaltrials |
| NCT00496509 | Phase I Efficacy On Vascular Permeability In Patients With Advanced Colorectal Cancer | completed | Phase 1 | 24 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Aug 26, 2016 | clinicaltrials |
| NCT00047840 | This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer. | completed | Phase 2 | 129 | Genzyme, a Sanofi CompanyINDUSTRY | 3 | Aug 25, 2016 | clinicaltrials |
| NCT00071188 | ZD6474 Alone or in Combination With Paclitaxel and Carboplatin in Subjects With Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) | completed | Phase 2 | — | Genzyme, a Sanofi CompanyINDUSTRY | 9 | Aug 25, 2016 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials